TY - JOUR
T1 - Developing new treatments for Alzheimer's disease
T2 - The who, what, when, and how of biomarker-guided therapies
AU - Lyketsos, Constantine G.
AU - Szekely, Christine A.
AU - Mielke, Michelle M.
AU - Rosenberg, Paul B.
AU - Zandi, Peter P.
PY - 2008/10
Y1 - 2008/10
N2 - This synthetic review presents an approach to the use of biomarkers for the development of new treatments for Alzheimer's disease (AD). After reviewing the process of translation as applied to AD, the paper provides a general update on what is known about the biology of the disease, and highlights currently available treatments. This is followed by a discussion of future drug development for AD emphasizing the roles that biomarkers are likely to play in this process: (1) define patients who are going to progress rapidly for the purpose of trial enrichment; (2) differentiate disease and therapeutically relevant AD subtypes; (3) assess the potential activity of specific therapies in vivo or ex vivo; and (4) measure the underlying disease state, so as to (a) detect disease and assess drug response in asymptomatic patients, (b) serve as a secondary outcome measure in clinical trials of symptomatic patients, and (c) decide if further development of a treatment should be stopped if not likely to be effective. Several examples are used to illustrate each biomarker utility in the AD context.
AB - This synthetic review presents an approach to the use of biomarkers for the development of new treatments for Alzheimer's disease (AD). After reviewing the process of translation as applied to AD, the paper provides a general update on what is known about the biology of the disease, and highlights currently available treatments. This is followed by a discussion of future drug development for AD emphasizing the roles that biomarkers are likely to play in this process: (1) define patients who are going to progress rapidly for the purpose of trial enrichment; (2) differentiate disease and therapeutically relevant AD subtypes; (3) assess the potential activity of specific therapies in vivo or ex vivo; and (4) measure the underlying disease state, so as to (a) detect disease and assess drug response in asymptomatic patients, (b) serve as a secondary outcome measure in clinical trials of symptomatic patients, and (c) decide if further development of a treatment should be stopped if not likely to be effective. Several examples are used to illustrate each biomarker utility in the AD context.
UR - http://www.scopus.com/inward/record.url?scp=50149118691&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=50149118691&partnerID=8YFLogxK
U2 - 10.1017/S1041610208007382
DO - 10.1017/S1041610208007382
M3 - Review article
C2 - 18498669
AN - SCOPUS:50149118691
SN - 1041-6102
VL - 20
SP - 871
EP - 889
JO - International psychogeriatrics
JF - International psychogeriatrics
IS - 5
ER -